Key result
Surgical septal myectomy remains the gold standard treatment for symptomatic hypertrophic cardiomyopathy, providing excellent outcomes with less than 1% mortality in experienced, high-volume centers.
Septal myectomy is the gold standard treatment for symptomatic hypertrophic cardiomyopathy and requires a personalized approach addressing various anatomical components.
Supports referral to high-volume centers for myectomy in symptomatic HCM; leaves open need for randomized comparisons with emerging options.
Septal myectomy is currently the gold standard treatment for symptomatic patients with hypertrophic cardiomyopathy. The procedure needs to be tailored and performed in a personalized fashion, taking into consideration the anatomical spectrum of this disease. The procedure needs to address the various components that contribute to the clinical and pathological picture of this disease including, the fibrous trigones, accessory tissues, papillary muscles, mitral valve and myocardial bridges. The operation can be performed with very low mortality and morbidity in high-volume experienced centers with predictable excellent short and long-term outcomes. There is a need for broadening the experience of this procedure to the rest of the world and for future development of new enhanced precision imaging and surgical tools.
No takes yet. Share an insight, caveat, or question.
Kindi et al. (2018) conducted an editorial in Hypertrophic cardiomyopathy. Surgical septal myectomy was evaluated. Surgical septal myectomy remains the gold standard treatment for symptomatic hypertrophic cardiomyopathy, providing excellent outcomes with less than 1% mortality in experienced, high-volume centers.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: